Anti-metastatic effect and mechanisms of Wenshen Zhuanggu Formula in human breast cancer cells. (13th March 2015)

• Record Type: Journal Article
• Authors: Han, Xiang-hui; Wang, Chun-li; Xie, Yan; Ma, Jiang; Zhang, Xiao-hui; Hu, Qian-wen; Lin, Ge; Liu, Sheng; Lu, Jin-gen
• Is Part Of: Journal of ethnopharmacology. Volume 162(2015)
• Page Start: 39
• Page End: 46
• Publication Date: 2015-03-13
• Subjects: Psoralen (PubChem CID: 6199) -- Isopsoralen (PubChem CID: 10658) -- Osthole (PubChem CID: 10228); Wenshen Zhuanggu Formula -- Traditional Chinese medicine -- Mesenchymal stem cells -- Breast cancer -- Metastases; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2014.12.036
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Wenshen Zhuanggu Formula (WSZG), a traditional Chinese medicine (TCM) empirical prescription, has been used to treat the patients with breast cancer bone metastasis as an adjuvant in clinical practice. To explore the anti-metastatic activity and potential mechanisms of WSZG-containing serum (WSZG-CS) on highly bone-metastatic human breast cancer MDA-MB-231BO cells. Materials and methods: MDA-MB-231BO cells were cultured alone or co-cultured with bone marrow-derived mesenchymal stem cells (BMSCs). Invasion assays were carried out in Matrigel-coated Transwell chambers. CC chemokine 5 (CCL5) and interleukin (IL)-17B secretion levels were detected by ELISA. CCR5 and IL-17BR protein expression levels were determined by immunocytochemistry and Western blot analysis. Results: Compared with control serum, WSZG-CS significantly inhibited BMSC induced MDA-MB-231BO breast cancer cell invasion, reduced CCL5 and IL-17B levels in co-culture supernatants, and downregulated CCR5 and IL-17BR protein expression in breast cancer cells co-cultured with BMSCs. Conclusions: WSZG-CS exerts an anti-metastatic activity against MDA-MB-231BO breast cancer cells, due to its ability to mitigate the interaction between BMSCs and breast cancer cells mediated via the CCL5/CCR5 and IL-17B/IL-17BR signaling pathways. Graphical abstract: Wenshen Zhuanggu Formula (WSZG) exerted an anti-metastatic activity against MDA-MB-231BO breast cancer cells, due to its ability to mitigate the interaction between BMSCs and breast cancer cells mediated via the CCL5/CCR5 and IL-17B/IL-17BR signaling pathways.